| __timestamp | Takeda Pharmaceutical Company Limited | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 520990000000 | 18516000 |
| Thursday, January 1, 2015 | 535405000000 | 34140000 |
| Friday, January 1, 2016 | 558755000000 | 51872000 |
| Sunday, January 1, 2017 | 495921000000 | 71772000 |
| Monday, January 1, 2018 | 659690000000 | 97501000 |
| Tuesday, January 1, 2019 | 1089764000000 | 118590000 |
| Wednesday, January 1, 2020 | 994308000000 | 169802000 |
| Friday, January 1, 2021 | 1106846000000 | 7491000 |
| Saturday, January 1, 2022 | 1244072000000 | 8799000 |
| Sunday, January 1, 2023 | 1431505000000 | 253598000 |
| Monday, January 1, 2024 | 1431505000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical landscape, cost efficiency is paramount. Takeda Pharmaceutical Company Limited and Xencor, Inc. offer a fascinating study in contrasts. Over the past decade, Takeda's cost of revenue has surged by approximately 175%, peaking in 2023. This growth reflects its expansive operations and strategic acquisitions. In contrast, Xencor, Inc., a smaller biotech firm, has seen its cost of revenue fluctuate, with a notable spike in 2023, reaching its highest point in the dataset.
From 2014 to 2023, Takeda's cost of revenue efficiency highlights its robust market presence, while Xencor's data reveals the volatility typical of smaller biotech firms. Notably, Xencor's data for 2024 is missing, indicating potential reporting delays or strategic shifts. This comparison underscores the diverse strategies within the pharmaceutical sector, where size and scale significantly impact financial metrics.
Comparing Cost of Revenue Efficiency: Novo Nordisk A/S vs Takeda Pharmaceutical Company Limited
Novartis AG vs Xencor, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Sanofi vs Xencor, Inc.
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Ionis Pharmaceuticals, Inc.
Cost of Revenue Comparison: Takeda Pharmaceutical Company Limited vs Xenon Pharmaceuticals Inc.
Cost Insights: Breaking Down Takeda Pharmaceutical Company Limited and HUTCHMED (China) Limited's Expenses
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Mesoblast Limited
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Travere Therapeutics, Inc.
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs BioCryst Pharmaceuticals, Inc.
Bio-Techne Corporation vs Xencor, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: HUTCHMED (China) Limited vs Xencor, Inc.
Cost of Revenue: Key Insights for Wave Life Sciences Ltd. and Xencor, Inc.